monday.com forecasts lower Q4 margin as AI investment accelerates

Image: Primary

Published Monday, November 9, 2026 · 9:07 AM EST

monday.com forecasts a Q4 non-GAAP operating margin of approximately 18%, down from 24% in Q3, as it increases investment in enterprise sales, product development and AI, 24/7 Wall St. reported. Management guided Q4 revenue to $380 to $382 million and acknowledged near-term operational headwinds from its AI transition. Q3 revenue rose 19% to $377.5 million. Sales and marketing expense fell to $149.1 million from $165.8 million a year earlier, helping lift profitability. AI products reached $36 million in annual recurring revenue, and monday agents surpassed 6 million interactions in less than two quarters. Operating cash flow fell to $20.4 million from $95.1 million.

Sources

24/7 Wall St.

Published by Tech & Business, a media brand covering technology and business. This story was sourced from 24/7 Wall St. and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

Capital Products

U.S. Series A funding reaches $42 billion as deal counts hold steady

U.S. startups raised $42 billion in Series A funding through October 2026, up roughly 60% year over year, while deal counts remained on pace with recent years, Crunchbase data shows.

Products

Ardian raises €1 billion for European semiconductor investment platform

Ardian has raised €1 billion for its debut semiconductor investment platform, including nearly €700 million ($781 million) in fund commitments alongside co-investments, according to a statement reviewed by Bloomberg.

Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.

Ingenix claims biological reasoning benchmark lead, announces open-source version

Ingenix says its 9-billion-parameter Thalamus Reasoning model ranks first among 29 models on LongevityBench, which tests language models on cellular aging research.